Healthcare Equipment and Supplies
Company Overview of Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company’s flagship product is the t:slim insulin delivery system that comprises t:slim pump, its disposable insulin cartridge, and an infusion set. It also provides t:flex insulin delivery system that includes t:flex pump, its 480-unit disposable insulin cartridge, and an infusion set; and t:slim G4 insulin delivery system, a touch-screen pump with an integrated CGM system. In addition, the company offers t:connect diabetes management application, a cloud-based data management application, which provides a visual way...
11045 Roselle Street
San Diego, CA 92121
Founded in 2006
Key Executives for Tandem Diabetes Care, Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $566.3K
Chief Financial Officer, Executive Vice President and Treasurer
Total Annual Compensation: $360.4K
Chief Operating Officer and Executive Vice President
Total Annual Compensation: $360.4K
Compensation as of Fiscal Year 2015.
Tandem Diabetes Care, Inc. Key Developments
Tandem Diabetes Care, Inc. Receives FDA Clearance of Remote Software Update Tool for Insulin Pumps
Jul 14 16
Tandem Diabetes Care®, Inc. announced U.S. Food and Drug Administration (FDA) clearance of the Tandem Device Updater, a Mac® and PC-compatible tool for the remote update of Tandem insulin pump software. The first use of the Tandem Device Updater will be for deployment of the latest t:slim® Insulin Pump software to in-warranty t:slim Pumps purchased before April 2015. This updated software began shipping on new t:slim Pumps as of April 2015 and includes a variety of product enhancements for convenience and flexibility. Future software improvements and enhancements will be implemented through the Tandem Device Updater as they are cleared for commercial distribution. The company intends to roll out the Tandem Device Updater first to early t:slim Pump users throughout the summer in a series of test groups, followed by an expanded launch later this year.
Tandem Diabetes Care, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016; Revises Earnings Guidance for the Year 2016; Provides Earnings Guidance for the Fourth Quarter of 2016
Apr 28 16
Tandem Diabetes Care, Inc. reported unaudited earnings results for the first quarter ended March 31, 2016. For the quarter, the company reported sales of $20,058,000 against $12,308,000 a year ago. Operating loss was $19,238,000 against $20,410,000 a year ago. Net loss was $20,484,000 against $21,208,000 a year ago. Basic and diluted net loss per share was $0.68 against $0.83 a year ago.
For the year 2016, the company now estimates sales to be in the range of $108 million to $115 million, which represents annual sales growth of 48% to 58% compared to 2015. The company's prior sales guidance range was $105 million to $112 million. Approximately $5.0 million to $6.0 million of depreciation and amortization.
For the fourth quarter of 2016, the company expects EBITDA-positive.
Tandem Diabetes Care, Inc. to Report Q1, 2016 Results on Apr 28, 2016
Apr 14 16
Tandem Diabetes Care, Inc. announced that they will report Q1, 2016 results After-Market on Apr 28, 2016
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|